A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer

C Qvortrup; Benny Vittrup Jensen; T Fokstuen; Svend Erik Nielsen; N Keldsen; B Glimelius; B Bjerregaard; J Mejer; F O Larsen; Per Pfeiffer

doi:10.1093/annonc/mdp272

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer

C Qvortrup, Benny Vittrup Jensen, T Fokstuen, Svend Erik Nielsen, N Keldsen, B Glimelius, B Bjerregaard, J Mejer, F O Larsen, Per Pfeiffer

32 Citationer (Scopus)

Abstract

Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity.

Originalsprog	Engelsk
Tidsskrift	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind	21
Udgave nummer	1
Sider (fra-til)	87-91
Antal sider	5
DOI	https://doi.org/10.1093/annonc/mdp272
Status	Udgivet - 1 jan. 2010

Adgang til dokumentet

10.1093/annonc/mdp272

Citationsformater

Qvortrup, C., Jensen, B. V., Fokstuen, T., Nielsen, S. E., Keldsen, N., Glimelius, B., Bjerregaard, B., Mejer, J., Larsen, F. O., & Pfeiffer, P. (2010). A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 21(1), 87-91. https://doi.org/10.1093/annonc/mdp272

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. / Qvortrup, C; Jensen, Benny Vittrup; Fokstuen, T et al.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 21, Nr. 1, 01.01.2010, s. 87-91.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Qvortrup, C, Jensen, BV, Fokstuen, T, Nielsen, SE, Keldsen, N, Glimelius, B, Bjerregaard, B, Mejer, J, Larsen, FO & Pfeiffer, P 2010, 'A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, bind 21, nr. 1, s. 87-91. https://doi.org/10.1093/annonc/mdp272

Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010 jan. 1;21(1):87-91. doi: 10.1093/annonc/mdp272

Qvortrup, C ; Jensen, Benny Vittrup ; Fokstuen, T et al. / A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010 ; Bind 21, Nr. 1. s. 87-91.

@article{527382b172bb4886ba4030cff90d31ae,

title = "A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer",

abstract = "Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity.",

author = "C Qvortrup and Jensen, {Benny Vittrup} and T Fokstuen and Nielsen, {Svend Erik} and N Keldsen and B Glimelius and B Bjerregaard and J Mejer and Larsen, {F O} and Per Pfeiffer",

year = "2010",

month = jan,

day = "1",

doi = "10.1093/annonc/mdp272",

language = "English",

volume = "21",

pages = "87--91",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "1569-8041",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer

AU - Qvortrup, C

AU - Jensen, Benny Vittrup

AU - Fokstuen, T

AU - Nielsen, Svend Erik

AU - Keldsen, N

AU - Glimelius, B

AU - Bjerregaard, B

AU - Mejer, J

AU - Larsen, F O

AU - Pfeiffer, Per

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity.

AB - Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity.

U2 - 10.1093/annonc/mdp272

DO - 10.1093/annonc/mdp272

M3 - Journal article

C2 - 19622596

SN - 1569-8041

VL - 21

SP - 87

EP - 91

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 1

ER -

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater